Alden Global Capital Exits Position in BioDelivery Sciences International (BDSI)

BioDelivery Sciences International (BDSI) : Alden Global Capital has sold out all of its stake in BioDelivery Sciences International during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 133,500 shares of BioDelivery Sciences International which is valued at $269,670.

Other Hedge Funds, Including , Granahan Investment Management Incma reduced its stake in BDSI by selling 70,680 shares or 9.54% in the most recent quarter. The Hedge Fund company now holds 669,950 shares of BDSI which is valued at $1.4 Million. BioDelivery Sciences International makes up approx 0.05% of Granahan Investment Management Incma’s portfolio. Penn Capital Management Co Inc sold out all of its stake in BDSI during the most recent quarter. The investment firm sold 1,314,623 shares of BDSI which is valued $2.7 Million.Teacher Retirement System Of Texas boosted its stake in BDSI in the latest quarter, The investment management firm added 1,619 additional shares and now holds a total of 6,140 shares of BioDelivery Sciences International which is valued at $12,403. Numeric Investors sold out all of its stake in BDSI during the most recent quarter. The investment firm sold 40,000 shares of BDSI which is valued $92,000. Foresite Capital Management Iii added BDSI to its portfolio by purchasing 207,498 company shares during the most recent quarter which is valued at $477,245. BioDelivery Sciences International makes up approx 0.36% of Foresite Capital Management Iii’s portfolio.

BioDelivery Sciences International opened for trading at $2.01 and hit $2.17 on the upside on Wednesday, eventually ending the session at $2.1, with a gain of 5.00% or 0.1 points. The heightened volatility saw the trading volume jump to 10,81,459 shares. Company has a market cap of $113 M.

On the company’s financial health, BioDelivery Sciences International reported $-0.36 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.35. The company had revenue of $3.00 million for the quarter, compared to analysts expectations of $2.76 million. The company’s revenue was down -77.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.16 EPS.

Many Wall Street Analysts have commented on BioDelivery Sciences International. Shares were Reiterated by Piper Jaffray on May 12, 2016 to “Overweight” and Lowered the Price Target to $ 4 from a previous price target of $6 .BioDelivery Sciences International was Downgraded by Cantor Fitzgerald to ” Hold” on May 11, 2016. Shares were Reiterated by FBR Capital on May 4, 2016 to “Outperform” and Lowered the Price Target to $ 9 from a previous price target of $12 .

BioDelivery Sciences International Inc. is a specialty pharmaceutical company. The Company develops and commercializes either on its own or in partnerships with third parties applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology a small erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product ONSOLIS (fentanyl buccal soluble film) as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate BELBUCA utilize its BEMA technology.

Leave a Reply

BioDelivery Sciences International - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioDelivery Sciences International. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.